VBI Vaccines Inc.

VBI Vaccines — Technical Presentation (August 2020)

9 slides from VBI Vaccines's technical presentation, Aug 26, 2020

  1. Slide 1: Preclinical Coronavirus Program Data

    Ss (> VBI VACCINES NM Preclinical Coronavirus Program Data Jeff Baxter, CEO; David E. Anderson, CSO NASDAQ: VBIV AUGUST 26 2020

  2. Slide 2: Forward-Looking Statements

    ee Forward-Looking Statements Certain statements in this press release that are forward-looking and not statements of historical fact are forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are forward-looking inform

  3. Slide 3: VBI-2900: Coronavirus Program with Two Optimized Vaccine Candidates

    ee VBI-2900: Coronavirus Program with Two Optimized Vaccine Candidates (VBI-2901 & VBI-2902) Vaccine Candidates Selected for Human Clinical Studies Based on Data From Three Preclinical Mouse Studies Objectives of Preclinical Studies ized Vaccine Candidates Assess the impact of: Common internal eVLP

  4. Slide 4: High-Titer COVID-19 Convalescent Sera Used as Benchmarking Data

    High-Titer COVID-19 Convalescent Sera Used as Benchmarking Data Convalescent Sera From 20 Individuals Who Had Contracted and Recovered From COVID-19 Were Collected For Comparison Collected from individuals who High-Titer | mounted e robust, high-titer antibody emerging literature, variance exists bi

  5. Slide 5: 4x and 64x Higher Neutralizing Antibody GMT Induced with Optimized eVLPs

    ee 4x and 64x Higher Neutralizing Antibody GMT Induced with Optimized eVLPs after 1 and 2 Doses, Respectively, Compared to High-Titer Convalescent Sera Optimized Neutralizing Activity Seen With eVLPs Expressing Stabilized, Modified Pre- fusion Form of SARS-CoV-2 Spike Protein Native SARS-CoV-2 Spike

  6. Slide 6: Optimized eVLPs Induced 10x Higher Antibody Binding GMT

    Optimized eVLPs Induced 10x Higher Antibody Binding GMT Compared to Both High-Titer Convalescent Sera and Recombinant Constructs After One Dose 7 g 10° is = Antibody Binding Titer (1/x) 103 High-Titer Recombinant eVLP Modified Pre-fusion _Pre-fusion Low-Titer Convalescent Sera Spike Protein Spike Pr

  7. Slide 7: Trivalent eVLP Offered Additional Breadth of Reactivity Across Coronaviruses

    Trivalent eVLP Offered Additional Breadth of Reactivity Across Coronaviruses The Trivalent eVLP Vaccine Construct Further Induced Antibody Binding Titers Across COVID-19, SARS, and MERS Spike Proteins in Addition to Broadening Reactivity to Seasonal Circulating Coronavirus Not Expressed in the Vacci

  8. Slide 8: VBI-2900 Data Summary & Next Steps

    ee VBI-2900 Data Summary & Next Steps Preclinical data demonstrated: F nducriondé tugs ig activity and antibody binding activity after one dose with eVLPs expressing the stabilized, modified pre-fusion form of the COVID-19 spike protein > potential for one-dose vaccines ST” wacmacea weaese reactivit

  9. Slide 9: Wie iZ

    AW WW) \ % Wie iZ y = W S “my VBI Vaccines Inc. 222 Third Street, Suite 2241 Cambridge, MA 02142 (617) 830-3031 info@vbivaccines.com

VBI Vaccines — Technical Presentation (August 2020) on 6ix